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Introduction
Population-based cancer registries (CRs) are an important
source of data for health policies, surveillance and epi-
demiological research. Cancer incidence or survival
measures derived from such data depend on the com-
pleteness of case ascertainment, that is the extent to
which all diagnosed neoplasms in the resident population
are included in the registry database.
Several methods for assessing the completeness of
registration have been devised and evaluated (Bullard
et al., 2000; Silcocks and Robinson, 2007; Schmidtmann,
2008; Parkin and Bray, 2009). Semiquantitative methods
assess completeness indirectly without quantifying the
number of missing cases. These include historic data
methods checking the stability of incidence rates over
time or comparing them with standard values, given that
such standards are available (Curado et al., 2007; Hackl
et al., 2011). The average number of notifications per case
is often reported, which is expected to be correlated with
completeness, whereas an unusually high proportion of
diagnoses on the basis of histology or cytology/haema-
tology (MV%) might indicate over-reliance on pathology
laboratories as sources of information, thus indicating
potential under-registration (Bray and Parkin, 2009).
Another indirect measure of completeness is the pro-
portion of cases where registration was initiated by a
death certificate (DCN%). If CRs rely on death certifi-
cates to a large extent, a number of missed diagnoses are
to be expected because of the well-documented inaccu-
racy and lack of specificity of the certified causes of death
(Mathers et al., 2005). Furthermore, the probability for a
cancer diagnosis to appear on the death certificate
decreases with time after diagnosis (Bullard et al., 2000).
Completeness of cancer registration can also be assessed
by comparing the mortality/incidence ratios (MI ratios)
with reference registries considered to be complete and
to share the same expected ratios (Haberland et al., 2001;
Hofferkamp, 2008). Reference MI ratios are not required
if the MI ratio is compared with relative survival (RS)
estimates from the same CR because both are expres-
sions of the same case fatality rate (MI-Surv method)
(Parkin and Bray, 2009; Vostakolaei et al., 2010).
Quantitative methods aim to directly estimate the num-
ber of missed diagnoses. Traditionally, they comprise
variations of the capture–recapture design, where the
registry database is compared with another collection of
cancer diagnoses, for example data collected for clinical
or epidemiological studies or administrative datasets such
as the national vital statistics. A novel and simpler
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method was introduced by Bullard et al., 2000. This so-
called Flow method models the logical flow of data in the
registration system. The Flow method has been vali-
dated using simulated data (Silcocks and Robinson, 2007)
and is currently the standard practice in the UK (NHS
Cancer Plan, 2004). The EUROCOURSE Workpackage
on completeness and timeliness of cancer registration
data in Europe specifically encourages a wider dis-
semination of the Flow method (Zanetti et al., 2010).
A survey on the different completeness methods used by
European CRs was conducted recently (Zanetti et al.,
2015). Only half of the responding registries declared the
use of at least one quantitative method and only one in
five stated that they had published the results in a peer-
reviewed journal. Hence, there seems to be a reporting
deficit on the levels of completeness in many European
CRs despite the importance of completeness for
unbiased statistics.
Methods
Source of cancer incidence data
This study is based on the National Core Dataset man-
aged by the National Institute for Cancer Epidemiology
and Registration with the purpose of national cancer
monitoring in Switzerland. All 10 Swiss CRs in operation
since at least 2006 are included in this report: Basel (BA),
Fribourg (FR), Geneva (GE), Grison and Glarus (GG),
Neuchâtel and Jura (NJ), St. Gallen-Appenzell (SG),
Ticino (TI), Valais (VS), Vaud (VD) and Zurich (ZH).
Included are malignant primary cancer cases. Vital status
was followed up until at least 2012. The diagnosis period
2006 to 2011 was pooled, except for BA, where
2006–2009 was available at the time of analysis. All can-
cer diagnoses (excluding nonmelanotic skin cancer)
amounted to 9350 (BA), 7270 (FR), 13 520 (GE), 7250
(GG), 7580 (NJ), 14 520 (SG), 11 520 (TI), 9420 (VS),
20 610 (VD) and 36 530 (ZH).
Source of cancer-specific mortality data
Registration of death is mandatory. The Swiss cause of
death statistics is comprehensive and based on data from
civil registries and death certificates issued by doctors
(Roy and Junker, 2014). The coding is based on the 10th
revision of the International Classification of Diseases
coding system (ICD-10) and is conducted by the Federal
Statistical Office according to rules defined by the WHO
since 1995. Deaths from 2006 to 2011 were pooled
(in BA: 2006–2009) for cancer-specific mortality rates.
Source of population data
Permanent residential population at mid-year was pro-
vided by the Federal Statistical Office. The permanent
resident population comprises all Swiss citizens with
main place of residence in Switzerland, and foreign citi-
zens with a residence permit for at least 12 months.
MI-Surv method
The crude ratio of mortality to incidence rates (MI ratio)
and the crude complement of relative survival (1−RS)
were derived for identical periods of time and regional
populations at risk. The statistical test comparing MI
ratios of individual CRs with the nationally pooled MI
ratio was performed according to Parkin and Bray (2009).
RS estimation excluded cases with a death certificate
as the only source of information (DCO) (2.3%). Patients
with multiple primary tumours were included. Cases
without active follow-up were excluded (1.7%). RS
was calculated as the ratio of the observed survival of
cancer cases and the expected survival of individuals in
the general population matching in age, sex and calendar
year of death (Ederer et al., 1961). Expected cancer sur-
vival was estimated using the Ederer II method applied
to all-cause mortality tables (Ederer et al., 1959). RS was
estimated using the strs command (version 1.4.2) written
by Dickman and Coviello (2015). The period survival
approach (Brenner and Gefeller, 1996) was applied with
follow-up dates 2006–2012. Five-year RS was used for
the MI-Surv method for all types of cancer, except breast
and prostate cancer, where, to comply with the assump-
tion of negligible excess hazard inherent to the MI-Surv
method, the 10-year RS was considered more adequate
(Dehler et al., 2013; Bouchardy et al., 2015). VD was not
analysed with the MI-Surv method because information
on survival was unavailable at the time of analysis.
Flow method
Completeness of case ascertainment was modelled as
described in Bullard et al. (2000). The Flow method
estimates three processes depending on time t after
diagnosis: survival times s(t), intervals from diagnosis
until registration during the patient lifetime u(t) and
proportions of death certificates that retain a mentioning
of cancer m(t). Patients not yet captured by registration
are either ‘still missing’ but alive or ‘lost’ because they
have died, have not been registered during life and their
death certificate lacked a mention of cancer. The esti-
mated completeness is the proportion neither ‘still
missing’ nor ‘lost’. The variance and confidence interval
for completeness and lost proportions were derived with
the direct bootstrap method (1000 samples). For indivi-
duals with multiple primary diagnoses, only the first
diagnosis was accepted to comply with the assumption of
independent cases. Cumulative observed survival s(t) was
estimated on the basis of diagnoses 2006–2011 for all
CRs. The probability of failure of registration before
death u(t) was estimated on the basis of registered
patients who died 2007–2012, except for FR, where
deaths 2006–2012 were used, because of the small
number of cases. A lower limit of 50 cases was required
for u(t) estimation, which excluded Hodgkin lymphoma.
Time intervals from diagnosis to registration were cen-
sured to 1 year before the date of death if death occurred
before registration because the registration probability
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increased by 15–20% during the year before death
(Lorez M, unpublished data) and u(t) should be applic-
able to all cases alive (Bullard et al., 2000). Estimation of
m(t) was based on time periods with less than 5% missing
information on cause of death. These were 2007–2011 for
TI, GE, SG, GG and period 2005 to 2009 for VS. In FR
(2006–2012) and ZH (2009–2012), up to 40% of deaths
were without information on causes; thus, estimation of
m(t) may be biased. Function m(t) was estimated by
logistic regression. BA, VD and NJ were not analysed
using the Flow method because of lack of information on
causes of death.
Results
For all 10 Swiss CRs in operation since at least 2006, the
DCN% was only 2.7% for all cancer sites combined
(Table 1). Systematically high DCN% were found for
hepatic and pancreatic cancer, up to 10.7 and 17.1%,
depending on CR.
The MV% was 94.2% overall (Table 1). CR-specific MV
% were tested by cancer type for being significantly
greater than the pool of all 10 Swiss CRs (Bray and
Parkin, 2009). As a result, only hepatic cancer in BA was
flagged (MV= 94.4%).
The ratios of crudemortality and incidence rates (MI ratio), by
cancer type and CR, were compared with the pooled MI
ratios (Supplementary Table S1, Supplemental digital content
1, http://links.lww.com/EJCP/A166 ). Significantly high MI ratios
(expressed as %) were found in BA for cancers of liver (146%),
pancreas (139%), oesophagus (112%), ovary (92%), multiple
myeloma (86%), melanoma (19%) and all sites combined
(49%), and isolated findings in FR for kidney cancer (51%)
and in NJ for Hodgkin lymphoma (22%).
Differences between MI ratio and 1−RS (ΔMI-Surv) by
cancer type and CR are listed in Table 2. Significant
ΔMI-Surv values greater than + 10% are flagged as
potentially under-registered. Flagging showed two pat-
terns. First, lymphoid leukaemia was systematically
marked in a majority of CRs and in all CRs combined
(14.0%). Second, BA was repeatedly flagged: for hepatic
(62.2%), pancreatic (54.3%) and ovarian cancer (42.2%),
and for all sites combined (11.0%). Isolated flags occurred
for ovarian cancer in ZH (13.1%) and Hodgkin lymphoma
in FR (12.2%).
Flow method-estimated levels of completeness at 3 years
after diagnosis are listed in Table 3. Completeness was
flagged if the point estimate was less than 80% or if the
confidence interval excluded 90%. Each CR tested
reached the international level for satisfactory com-
pleteness of 90% ~ 3 years after the diagnosis for all sites
combined, as well as for the majority of cancer types. The
only diagnostic group that seemed systematically under-
registered was again lymphoid leukaemia, which was
flagged in six of seven registries. CR-specific findings
were lower levels of completeness in ZH for prostate
cancer, kidney cancer and non-Hodgkin lymphoma, and
prostate cancer in VS. The yearly increase in complete-
ness, as well as in cases lost from registration, is shown in
Supplementary Table S2 (Supplemental digital content
2, http://links.lww.com/EJCP/A167) for all cancer types
combined. A majority of CRs reached completeness
levels of 90% already 2 years after diagnosis. In addition
to high completeness, the proportions of cases expected
to be lost for registration remained very low (< 2%), even
at 5 years after diagnosis.
Discussion
Our results showed overall high levels of completeness in
Swiss cancer registration. An indirect measure of com-
pleteness is the DCN%. In Switzerland, high DCN%
were found across all CRs only for hepatic (7.8%) and
pancreatic (11.1%) cancer (Table 1). This is not unusual,
but rather expected for cancers with a poor prognosis
(Pollock and Vickers, 1995). DCN% must be higher than
or equal to DCO%. The Swiss DCN% values are con-
sistent with mean DCO% of 8.0 and 7.1% for hepatic and
pancreatic cancer reported from 42 European CRs,
respectively (diagnoses 2003–2007; Forman et al., 2014).
However, high DCN% alone is not a strong indicator for
under-reporting, which is supported by the sparsity of
flagging for hepatic and pancreatic cancer estimated by
other methods in this study.
Another routinely used measure with implication for
completeness is the proportion of diagnoses with micro-
scopic verification, MV% (Table 1). Exceptionally high
MV% might indicate over-reliance on the pathology
laboratory as a source of information and failure to find
cases diagnosed by other means (Bray and Parkin, 2009).
BA was flagged for hepatic cancer with the unexpected
high value of 94.4% compared with the value of 56.7% for
Switzerland, which was similar to the mean of 47% from
56 CRs from European countries (Forman et al., 2014).
The MI ratio is expected to be similar to 1–RS assessed
in the same population at risk because both approximate
cancer-specific case fatality (Parkin and Bray, 2009;
Vostakolaei et al., 2010). MI ratios systematically greater
than their corresponding 1–RS values lead to a suspicion
of under-registration. We consistently observed MI ratios
significantly above the value of 1–RS for lymphoid leu-
kaemia (Table 2). Also, the Flow method reported
potential under-registration for lymphoid leukaemia in
the majority of CR, with completeness levels of 67–88%
at 3 years after diagnosis (Table 3). This result was not
unexpected because 80% of lymphoid leukaemia diag-
noses were of chronic types, compared with only 31% of
all myeloid leukaemia diagnoses. Chronic types of leu-
kaemia are often diagnosed in the outpatient setting,
which potentially circumvents capture and registration
compared with hospital-based diagnoses (Pritzkuleit
et al., 2008; Ess, 2009; Larsen et al., 2009; Craig et al.,
2012; Dimitrova and Parkin, 2015). These haematological
S144 European Journal of Cancer Prevention 2017, Vol 26 Supplement 2
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malignancies come to the attention of CRs only after
patients become hospitalized because the cancer pro-
gressed into a blast phase, causing long delays between
diagnosis date and registration date. Such delays in
registration of lymphoid leukaemia were apparent in
Swiss CRs. Supplementary Table S3, Supplemental
digital content 3, http://links.lww.com/EJCP/A168 tabulates
the time required to capture 90% of the finally registered
diagnoses for different types of cancer. Overall, it took
most CRs about 1 year to collect 90% of diagnoses, but it
differed by diagnostic group. Although breast cancer
diagnoses were captured rather quickly (0.6 years on
average), diagnoses for lymphatic leukaemia took the
longest (2.6 years on average).
We observed a pattern of significantly high ΔMI-Surv
values in BA (hepatic, pancreatic, ovarian cancer and all
sites combined). Together with the reported flags for
high DCN%, significantly high MV% and significantly
high MI ratios, it supports under-registration for at least
some of the cancer sites involved.
The Flow method, but not the MI-Surv method, flagged
prostate and kidney cancer and non-Hodgkin lymphoma
as possibly under-registered at 3 years after diagnosis in
ZH. ZH has in fact experienced reluctance in reporting of
cases by some of the data sources because of unresolved
issues of data protection legislation for the main part of
the incidence period in this report (2007–2011) (Dehler
et al., 2012). This might have caused the longer regis-
tration delay of about 2 years on average, compared with
1 year in other CRs (Supplementary Table S3, Supplemental
digital content 3, http://links.lww.com/EJCP/A167), as well as
lower completeness estimates for all cancers combined at
1–3 years after diagnosis shown in Supplementary Table S2
(Supplemental digital content 2, http://links.lww.com/EJCP/
A167). The issues with data protection legislation have been
resolved recently (Dehler et al., 2014).
Limitations
The methods used rested on a number of assumptions.
The value of ΔMI-Surv will be affected not only by
under-registration but also by inaccurate or incomplete
registration of causes of death, or biased RS estimates.
The quality of the Swiss vital statistics is high because
only about 3% of all deaths have an unknown cause (Roy
and Junker, 2014). We observed that 11% of all deaths
between 2006 and 2011 were assigned to ill-defined
codes as the principal cause (i.e. symptoms, signs, ill-
defined conditions, deaths from injuries where the intent
is not determined, cardiac arrest, heart failure, or cancer
codes for secondary, unspecified or multiple sites), which
places Swiss vital statistics in the high-quality to
medium-quality range compared with other European
countries (Mathers et al., 2005). Also, metastases may
have misled the doctor certifying the death about the
location of the primary cancer. The bias of ill-defined or
incorrect causes of death exerted on the MI-Surv method
are underestimation of the MI ratio, thus potentially
masking existing under-registration.
Excluding DCO cases from survival analysis may bias
survival as being too high (Robinson et al., 2007;
Holleczek and Brenner, 2012). The highest DCO% were
found in BA (17.1% for pancreatic cancer and 10.7% for
hepatic cancer) because trace-back is not systematically
performed. As ΔMI-Surv values in BA were large
(>50%), it is not likely that biased survival alone is
responsible. Breast and prostate cancer are candidates for
being affected by lead-time and length-time biases and
overdiagnosis because of screening. This would over-
estimate survival or underestimate the expected MI ratio,
and reduce the ability of the MI-Surv method to dis-
criminate against under-registration.
The Flow method assumes that patients are not regis-
tered from sources other than death certificates after
death, that is cases who died before registration and
whose death certificate lack a mention of cancer are lost
to the registration process (Bullard et al., 2000). The
proportion of registrations after death without cancer
mentioned in the death certificate to all registrations after
death amounted to 8% in ZH, 1% in FR, 7% in TI, 12%
in VS, 13% GE, 9% in SG and 11% in GG. The pro-
portion lost from registration will thus be slightly over-
estimated. As lost proportions were generally small
(Supplementary Table S2, Supplemental digital content
2, http://links.lww.com/EJCP/A167), this will not affect the
completeness value to a great extent.
Conclusion
Despite the fact that cancer is not yet mandatorily
reportable in Switzerland, neither the MI-Surv method
nor the Flow method detected signs of potential under-
ascertainment of cases for most types of cancer in any CR
tested, with the notable exception of lymphoid leukae-
mia. As next steps, we will follow up flagged cancer types
in individual CRs to substantiate these findings and
identify ways of improvement, such as optimized
matching of mortality to registration data. Future studies
will include in-depth analyses of completeness depend-
ing on factors such as age at diagnosis or analyses of
temporal completeness trends.
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